Brief: Inhibikase Therapeutics Inc Says 201 Trial Met Primary Endpoint Of Safety And Tolerability
29/01/2025 23:25
Jan 29 (Reuters) - Inhibikase Therapeutics Inc IKT.O :
* INHIBIKASE THERAPEUTICS INC - 201 TRIAL MET PRIMARY
ENDPOINT OF
SAFETY AND TOLERABILITY
* INHIBIKASE THERAPEUTICS INC - RISVODETINIB TREATMENT DID
NOT
SHOW IMPROVEMENT IN TOP HIERARCHICAL EFFICACY MEASURE
Source text: ID:n0001193125-25-015648
Further company coverage: IKT.O
((Reuters.Brief@thomsonreuters.com;))
Recent news on Inhibikase Therapeutics
See all newsBrief: Inhibikase Therapeutics Appoints Scott Wasserman To Board Of Directors
Inhibikase Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Inhibikase Q2 net loss widens on higher R&D, SG&A costs
Inhibikase Therapeutics, Inc. expected to post a loss of 11 cents a share - Earnings Preview
Brief: Inhibikase Therapeutics Prices Public Offering Of 46 Million Shares At $1.45 Per Share